Bone Biologics Stock Price, News & Analysis (OTC:BBLG) $0.41 -0.01 (-2.13%) (As of 04:30 PM ET) Add Compare Share Share Today's Range$0.40▼$0.4350-Day Range$0.42▼$0.7852-Week Range$0.40▼$13.20Volume158,308 shsAverage Volume369,659 shsMarket Capitalization$1.29 millionP/E RatioN/ADividend YieldN/APrice Target$67.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesOwnershipStock AnalysisAnalyst ForecastsChartHeadlinesOwnership Bone Biologics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside15,895.3% Upside$67.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($8.15) to ($10.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.54 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBone Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $67.50, Bone Biologics has a forecasted upside of 15,895.3% from its current price of $0.42.Amount of Analyst CoverageBone Biologics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for BBLG. Previous Next 0.0 Dividend Strength Dividend YieldBone Biologics does not currently pay a dividend.Dividend GrowthBone Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BBLG. Previous Next 0.6 News and Social Media Coverage Search Interest8 people have searched for BBLG on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bone Biologics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.90% of the stock of Bone Biologics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Bone Biologics are expected to decrease in the coming year, from ($8.15) to ($10.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bone Biologics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bone Biologics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBone Biologics has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bone Biologics Stock (OTC:BBLG)Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.Read More BBLG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BBLG Stock News HeadlinesNovember 20, 2023 | msn.comWhy Bone Biologics Stock (BBLG) Is Falling SharplyNovember 20, 2023 | finance.yahoo.comBone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 17, 2023 | msn.comWhy Bone Biologics Stock (BBLG) Is Getting Obliterated FridayNovember 16, 2023 | finance.yahoo.comBone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNovember 15, 2023 | finance.yahoo.comBBLG Offers Good Entry OpportunityNovember 14, 2023 | msn.comWhat Are Biologics?November 14, 2023 | morningstar.comBone Biologics Corp BBLGNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comSeptember 26, 2023 | finance.yahoo.comBone Biologics Provides Scientific Update on NB1 Bone Graft DeviceSeptember 24, 2023 | abcnews.go.comRobin Roberts' sister reflects on sibling's upcoming wedding after lifesaving bone marrow donationSeptember 22, 2023 | bbc.co.ukBone brothSeptember 15, 2023 | finance.yahoo.comInsider Buying: CFO Deina Walsh Acquires 8,000 Shares of Bone Biologics Corp (BBLG)September 13, 2023 | finance.yahoo.comCEO Jeff Frelick Buys 9,500 Shares of Bone Biologics Corp (BBLG)August 23, 2023 | nypost.comMan killed roommate, and lived with body in closet for monthsAugust 17, 2023 | detroitnews.comTB death in Michigan linked to contaminated bone graft materialAugust 15, 2023 | finance.yahoo.comBBLG Advances Crucial Technology and Solidifies FundingAugust 4, 2023 | msn.comSecond deadly TB outbreak linked to tainted bone graftsJuly 31, 2023 | msn.comDeadly tuberculosis outbreaks in US linked to tainted bone graftsJuly 6, 2023 | msn.comBone Biologics (BBLG) Price Target Increased by 738.89% to 38.51June 22, 2023 | marketwatch.comBioMedNewsBreaks - Bone Biologics Corporation (NASDAQ: BBLG) Announces $5M Underwritten Public OfferingJune 16, 2023 | msn.comBone Biologics stock plummets more than 50% after stock offering prices at deep discountJune 15, 2023 | msn.comBone Biologics slumps 50%, prices $5M offeringJune 15, 2023 | msn.comBone Biologics Nosedives on $5M Stock OfferingJune 15, 2023 | finance.yahoo.comBone Biologics Prices $5.0 Million Underwritten Public OfferingJune 8, 2023 | finance.yahoo.comBBLG - Bone Biologics CorporationJune 8, 2023 | finance.yahoo.comBBLG: BBLG Advances Crucial Technology and Solidifies FundingSee More Headlines Receive BBLG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bone Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today11/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTC Industry Medical Devices Sub-IndustryN/A SectorMedical Current SymbolOTC:BBLG CUSIPN/A CIKN/A Webwww.bonebiologics.com Phone781-552-4452FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Target$67.50 High Stock Price Target$67.50 Low Stock Price Target$67.50 Potential Upside/Downside+15,895.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($6.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,490,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-123.44% Return on Assets-82.64% Debt Debt-to-Equity RatioN/A Current Ratio3.95 Quick Ratio3.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.82 per share Price / Book0.23Miscellaneous Outstanding Shares3,134,000Free Float2,886,000Market Cap$1.32 million OptionableNot Optionable Beta0.08 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Jeffrey Frelick (Age 57)CEO & President Comp: $337.75kMs. Deina H. Walsh (Age 59)Chief Financial Officer Comp: $218.88kDr. Shun'ichi KurodaCo-Founder & Member of Scientific Advisory BoardKey CompetitorsMotus GINASDAQ:MOTSDynatronicsNASDAQ:DYNTNeuroMetrixNASDAQ:NUROAethlon MedicalNASDAQ:AEMDIntellipharmaceutics InternationalOTCMKTS:IPCIFView All Competitors BBLG Stock Analysis - Frequently Asked Questions Should I buy or sell Bone Biologics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bone Biologics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BBLG shares. View BBLG analyst ratings or view top-rated stocks. What is Bone Biologics' stock price target for 2024? 1 analysts have issued 1 year target prices for Bone Biologics' stock. Their BBLG share price targets range from $67.50 to $67.50. On average, they expect the company's stock price to reach $67.50 in the next twelve months. This suggests a possible upside of 15,895.3% from the stock's current price. View analysts price targets for BBLG or view top-rated stocks among Wall Street analysts. How have BBLG shares performed in 2023? Bone Biologics' stock was trading at $6.2910 at the beginning of 2023. Since then, BBLG shares have decreased by 93.3% and is now trading at $0.4220. View the best growth stocks for 2023 here. When did Bone Biologics' stock split? Bone Biologics shares reverse split before market open on Wednesday, June 7th 2023. The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Bone Biologics? Shares of BBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (OTC:BBLG) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bone Biologics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.